PATIENTS harboring nonbeta islet cell pancreatic tumors (Zollinger-Ellison syndrome [Z-E]) which elaborate a gastrin or "gastrin-like" substance are not easily differentiated from the more common peptic ulcer patients. Many of these patients with hypergastrinism are first treated medically or with surgical procedures for ordinary peptic ulcer disease. As a result, many succumb from the complications of gastric hypersecretion before a diagnosis of a gastrin-producing tumor can be confirmed.1
Gregory et al2 was the first to extract a "gastrin-like" material from a tumor obtained in a case of Z-E syndrome. Further studies on the nature of the gastric secretagogues extracted from two Z-E tumors indicate it to be the same as one or possibly both of the gastrin peptides isolated from human antral mucosa.3 The reports of Sircus4 and Bank et al5 of a gastric secretagogue, "presumably gastrin," in the circulation of Z-E patients have naturally
Wilson LSD, Mathison JA, Schulte WJ, Ellison EH. The Role of Bioassay in the Diagnosis of Ulcerogenic Tumors. Arch Surg. 1968;97(3):437–443. doi:10.1001/archsurg.1968.01340030097008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: